Peter Toogood's Email & Phone

Dr. Peter L. Toogood joined Lycera in 2007, after working as a research scientist and manager at Parke-Davis and Pfizer. He has led drug discovery teams in cancer, infectious disease and immunology and was an inventor of the first selective cyclin-dependent kinase 4 inhibitor to enter human clinical trials. Prior to joining Parke-Davis, Dr. Toogood was a faculty member in the department of chemistry at the University of Michigan. There, he established a research program in natural products total synthesis and chemical biology, funded by the National Institutes of Health and the National Science Foundation. Dr. Toogood is the author of more than 40 peer-reviewed publications; he holds 9 patents and is named as an inventor on an additional 20 pending patent applications. In addition to his work at Lycera, Dr. Toogood is an adjunct professor in the University of Michigan College of Pharmacy. Dr. Toogood received a Ph.D. from Imperial College in London and was a NATO postdoctoral fellow at Harvard University.